UBS analyst Andrea Alfonso lowered the firm’s price target on Idexx Laboratories (IDXX) to $640 from $730 and keeps a Neutral rating on the shares. The Q1 earnings outlook is cautious amid softer macro conditions and declining vet visit trends, though U.S. pet results are expected to hold up, the analyst tells investors in a research note. The firm is “less confident” Idexx can preserve its outlook for the full-year given the tough consumer backdrop.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDXX:
- Cloudflare upgraded, SolarEdge downgraded: Wall Street’s top analyst calls
- Idexx Laboratories initiated with a Neutral at Citi
- Idexx Laboratories announces Idexx Cancer Dx Panel availability in the UK
- Idexx Laboratories price target lowered to $675 from $775 at Stifel
- Idexx Laboratories management to meet with Piper Sandler